Fate Therapeutics Inc  

(Public, NASDAQ:FATE)   Watch this stock  
Find more results for fate
-0.10 (-2.82%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.30 - 3.63
52 week 1.46 - 6.92
Open 3.58
Vol / Avg. 0.00/219,637.00
Mkt cap 96.59M
P/E     -
Div/yield     -
EPS -1.08
Shares 28.89M
Beta     -
Inst. own 58%
Nov 1, 2016
Q3 2016 Fate Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 29, 2016
Fate Therapeutics Inc at Leerink Partners Rare Disease & IO Roundtable Series - 3:45PM EDT - Add to calendar
Sep 13, 2016
Fate Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Sep 7, 2016
Fate Therapeutics Inc at Wells Fargo Securities Healthcare Conference
Aug 8, 2016
Q2 2016 Fate Therapeutics Inc Earnings Call
Aug 8, 2016
Q2 2016 Fate Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -818.70% -1233.73%
Operating margin -779.36% -1142.82%
EBITD margin - -1114.03%
Return on average assets -62.52% -50.35%
Return on average equity -125.24% -90.37%
Employees 60 -
CDP Score - -


3535 General Atomics Ct Ste 200
SAN DIEGO, CA 92121-1140
United States - Map
+1-858-8751803 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
J. Scott Wolchko President, Chief Executive Officer, Principal Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
John D. Mendlein Ph.D. Vice Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Daniel D. Shoemaker Ph.D. Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
John Ferraro Vice President - Clinical Operations
Bio & Compensation  - Reuters
Wendy Levin Vice President - Clinical Development
Bio & Compensation  - Reuters
Walter Grubb Vice President - Business Development
Bio & Compensation  - Reuters
Cindy Tahl J.D. General Counsel
Bio & Compensation  - Reuters
Stewart Abbot Ph.D. Chief Development Officer
Bio & Compensation  - Reuters
Chris M. Storgard M.D. Chief Medical Officer
Bio & Compensation  - Reuters